{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:30:24Z","timestamp":1772119824247,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Alberta Cancer Foundation, Canada"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05351-z","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:48:13Z","timestamp":1764326893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis"],"prefix":"10.1007","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-5415","authenticated-orcid":false,"given":"Gloria","family":"Roldan Urgoiti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"de Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger Y.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Willson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Faruqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Nordal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Cairncross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona","family":"Leckie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice C.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Wee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"5351_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro-Oncol"},{"key":"5351_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5351_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306\u20132316. https:\/\/doi.org\/10.1001\/jama.2017.18718","journal-title":"JAMA"},{"key":"5351_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.ymthe.2025.03.004","volume":"33","author":"SL Begley","year":"2025","unstructured":"Begley SL, O\u2019Rourke DM, Binder ZA (2025) CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials. Mol Ther J Am Soc Gene Ther 33:2454\u20132461. https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.004","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"5351_CR5","doi-asserted-by":"publisher","first-page":"vdaf115","DOI":"10.1093\/noajnl\/vdaf115","volume":"7","author":"JTN Chan","year":"2025","unstructured":"Chan JTN, Henley-Waters J, Kayhanian S (2025) Chimeric antigen receptor (CAR)-T-cell therapy for glioblastoma: what can we learn from the early clinical trials? A systematic review. Neuro-Oncol Adv 7:vdaf115. https:\/\/doi.org\/10.1093\/noajnl\/vdaf115","journal-title":"Neuro-Oncol Adv"},{"key":"5351_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s11060-024-04881-2","volume":"171","author":"A Badani","year":"2025","unstructured":"Badani A, Ozair A, Khasraw M et al (2025) Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions. J Neurooncol 171:531\u2013547. https:\/\/doi.org\/10.1007\/s11060-024-04881-2","journal-title":"J Neurooncol"},{"key":"5351_CR7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-042524-025950","author":"J Li","year":"2025","unstructured":"Li J, Ross JL, Hambardzumyan D, Brat DJ (2025) Immunopathology of glioblastoma. Annu Rev Pathol. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-042524-025950","journal-title":"Annu Rev Pathol"},{"key":"5351_CR8","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1038\/s41467-025-56930-7","volume":"16","author":"S-P Weathers","year":"2025","unstructured":"Weathers S-P, Li X, Zhu H et al (2025) Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut Microbiome features: a single arm prospective phase I\/II trial. Nat Commun 16:3950. https:\/\/doi.org\/10.1038\/s41467-025-56930-7","journal-title":"Nat Commun"},{"key":"5351_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/neuonc\/noae193","volume":"27","author":"R Du","year":"2025","unstructured":"Du R, Zhang J, Lukas RV et al (2025) Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy? Neuro-Oncol 27:33\u201349. https:\/\/doi.org\/10.1093\/neuonc\/noae193","journal-title":"Neuro-Oncol"},{"key":"5351_CR10","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/life15071097","volume":"15","author":"C Moura","year":"2025","unstructured":"Moura C, Gouveia MJ, Vale N (2025) Repurposed antipsychotics as potential anticancer agents: clozapine efficacy and dopaminergic pathways in neuroblastoma and glioblastoma. Life Basel Switz 15:1097. https:\/\/doi.org\/10.3390\/life15071097","journal-title":"Life Basel Switz"},{"key":"5351_CR11","doi-asserted-by":"publisher","first-page":"20560","DOI":"10.1038\/s41598-025-05054-5","volume":"15","author":"S Dey","year":"2025","unstructured":"Dey S, Mathur P, Mukherjee S et al (2025) Repurposing of CNS accumulating drugs gemfibrozil and doxylamine for enhanced sensitization of glioblastoma cells through modulation of autophagy. Sci Rep 15:20560. https:\/\/doi.org\/10.1038\/s41598-025-05054-5","journal-title":"Sci Rep"},{"key":"5351_CR12","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1093\/brain\/aww355","volume":"140","author":"CC Poon","year":"2017","unstructured":"Poon CC, Sarkar S, Yong VW, Kelly JJP (2017) Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain J Neurol 140:1548\u20131560. https:\/\/doi.org\/10.1093\/brain\/aww355","journal-title":"Brain J Neurol"},{"key":"5351_CR13","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","volume":"186","author":"RR Maas","year":"2023","unstructured":"Maas RR, Soukup K, Fournier N et al (2023) The local microenvironment drives activation of neutrophils in human brain tumors. Cell 186:4546\u20134566e27. https:\/\/doi.org\/10.1016\/j.cell.2023.08.043","journal-title":"Cell"},{"key":"5351_CR14","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, Yu MW, Maritan SM et al (2023) Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature 614:555\u2013563. https:\/\/doi.org\/10.1038\/s41586-022-05680-3","journal-title":"Nature"},{"key":"5351_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-022-04047-y","volume":"159","author":"PM Bracci","year":"2022","unstructured":"Bracci PM, Rice T, Hansen HM et al (2022) Pre-surgery immune profiles of adult glioma patients. J Neurooncol 159:103\u2013115. https:\/\/doi.org\/10.1007\/s11060-022-04047-y","journal-title":"J Neurooncol"},{"key":"5351_CR16","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.tips.2025.07.006","volume":"46","author":"F Zhou","year":"2025","unstructured":"Zhou F, Mukherjee P, Mu J, Chen P (2025) Therapeutic potential of targeting macrophages and microglia in glioblastoma. Trends Pharmacol Sci 46:848\u2013862. https:\/\/doi.org\/10.1016\/j.tips.2025.07.006","journal-title":"Trends Pharmacol Sci"},{"key":"5351_CR17","doi-asserted-by":"publisher","first-page":"eaay9924","DOI":"10.1126\/scitranslmed.aay9924","volume":"12","author":"S Sarkar","year":"2020","unstructured":"Sarkar S, Yang R, Mirzaei R et al (2020) Control of brain tumor growth by reactivating myeloid cells with niacin. Sci Transl Med 12:eaay9924. https:\/\/doi.org\/10.1126\/scitranslmed.aay9924","journal-title":"Sci Transl Med"},{"key":"5351_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00401-020-02129-7","volume":"139","author":"KS Rawji","year":"2020","unstructured":"Rawji KS, Young AMH, Ghosh T et al (2020) Niacin-mediated rejuvenation of macrophage\/microglia enhances remyelination of the aging central nervous system. Acta Neuropathol (Berl) 139:893\u2013909. https:\/\/doi.org\/10.1007\/s00401-020-02129-7","journal-title":"Acta Neuropathol (Berl)"},{"key":"5351_CR19","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s13311-023-01376-2","volume":"20","author":"E Wuerch","year":"2023","unstructured":"Wuerch E, Urgoiti GR, Yong VW (2023) The promise of niacin in neurology. Neurother J Am Soc Exp Neurother 20:1037\u20131054. https:\/\/doi.org\/10.1007\/s13311-023-01376-2","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"5351_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jacl.2011.07.003","volume":"6","author":"AP Dunatchik","year":"2012","unstructured":"Dunatchik AP, Ito MK, Dujovne CA (2012) A systematic review on evidence of the effectiveness and safety of a wax-matrix niacin formulation. J Clin Lipidol 6:121\u2013131. https:\/\/doi.org\/10.1016\/j.jacl.2011.07.003","journal-title":"J Clin Lipidol"},{"key":"5351_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1532-5415.1992.tb01822.x","volume":"40","author":"JM Keenan","year":"1992","unstructured":"Keenan JM, Bae CY, Fontaine PL et al (1992) Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. J Am Geriatr Soc 40:12\u201318. https:\/\/doi.org\/10.1111\/j.1532-5415.1992.tb01822.x","journal-title":"J Am Geriatr Soc"},{"key":"5351_CR22","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/archinte.151.7.1424","volume":"151","author":"JM Keenan","year":"1991","unstructured":"Keenan JM, Fontaine PL, Wenz JB et al (1991) Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 151:1424\u20131432. https:\/\/doi.org\/10.1001\/archinte.151.7.1424","journal-title":"Arch Intern Med"},{"key":"5351_CR23","first-page":"313","volume":"34","author":"JM Keenan","year":"1992","unstructured":"Keenan JM, Wenz JB, Ripsin CM et al (1992) A clinical trial of oat bran and niacin in the treatment of hyperlipidemia. J Fam Pract 34:313\u2013319","journal-title":"J Fam Pract"},{"key":"5351_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1001\/archfami.5.10.567","volume":"5","author":"DM Aronov","year":"1996","unstructured":"Aronov DM, Keenan JM, Akhmedzhanov NM et al (1996) Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med 5:567\u2013575. https:\/\/doi.org\/10.1001\/archfami.5.10.567","journal-title":"Arch Fam Med"},{"key":"5351_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurother J Am Soc Exp Neurother 14:307\u2013320. https:\/\/doi.org\/10.1007\/s13311-016-0507-6","journal-title":"Neurother J Am Soc Exp Neurother"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05351-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05351-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:34:23Z","timestamp":1767702863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05351-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5351"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05351-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7889791\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Good Clinical Practice (ICH-GCP) Guidelines under a Clinical Trial Application (CTA) for a natural health product (NHP) with Health Canada. It obtained local ethics board approval (HREBA cc 20\u20130402) before starting. All patients signed informed consent. Data Safety Monitoring Committee (DSMC) meetings were planned per protocol at the completion of phase I, after the interim analysis and at the end of phase II. The trial is registered in clinicaltrials.gov as NCT04677049.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have consented to publish this paper. This material was accepted as poster in the Canadian Cancer Research Conference, Calgary AB, Nov 2\u20134, 2025.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}